The Experts below are selected from a list of 37653 Experts worldwide ranked by ideXlab platform
Soeren Mattke - One of the best experts on this subject based on the ideXlab platform.
-
breast implant associated anaplastic Large Cell Lymphoma a systematic review
Plastic and Reconstructive Surgery, 2015Co-Authors: Courtney A Gidengil, Zachary Predmore, Soeren Mattke, Kristin R Van Busum, Benjamin KimAbstract:Background:There is substantial evidence that a type of anaplastic Large Cell Lymphoma (ALCL) is associated with breast implants. However, the course in patients with breast implants seems to be unusually benign compared with other systemic ALCL. The purpose of this study was to identify and analyze
-
breast implant associated anaplastic Large Cell Lymphoma updated results from a structured expert consultation process
Plastic and reconstructive surgery. Global open, 2015Co-Authors: Zachary Predmore, K Van Busum, Soeren Mattke, Courtney A GidengilAbstract:Breast implant–associated anaplastic Large Cell Lymphoma (BIA-ALCL) is an uncommon entity. We previously published a systematic literature review of 29 cases of BIA-ALCL1 (recapitulated in a 2011 Food and Drug Administration alert)2 and a subsequent report from a structured, expert consultation panel, which agreed that there is a positive association between breast implants and anaplastic Large Cell Lymphoma (ALCL) development; anaplastic Lymphoma kinase (ALK)-negative ALCL that develops around breast implants is a clinically indolent disease with a favorable prognosis that is distinct from systemic ALK-negative ALCL; management should consist of removal of the involved implant and capsule, which is likely to prevent recurrence, and evaluation for other sites of disease; and adjuvant radiation or chemotherapy should not be offered to women with capsule-confined disease.3 Since then, additional BIA-ALCL case reports and series have been published,4–30 which we have summarized in an updated systematic review.31 Although BIA-ALCL has become increasingly recognized in the plastic surgery community, there has been little additional guidance made available to hematology/oncology providers as to how the diagnosis, management, and surveillance of this disease should be undertaken. Because much of the information in the literature is still incomplete and does not address important clinical topics related to BIA-ALCL, we conducted a follow-up structured expert consultation process that combined published evidence with expert assessment to garner additional insight on these important issues.
-
anaplastic Large Cell Lymphoma and breast implants a systematic review
Plastic and Reconstructive Surgery, 2011Co-Authors: Benjamin Kim, Carol P Roth, Christopher Schnyer, Kevin C. Chung, Kristin R Van Busum, Leroy V Young, Soeren MattkeAbstract:Background:In recent years, there have been growing concerns about a possible association of non-Hodgkin's Lymphoma—in particular, anaplastic Large Cell Lymphoma (ALCL)—and breast implants. The purpose of this study was to identify and analyze all reported cases of non-Hodgkin's Lymphoma occurring i
-
anaplastic Large Cell Lymphoma and breast implants results from a structured expert consultation process
Journal of Clinical Oncology, 2011Co-Authors: Carol P Roth, V L Young, K Van Busum, Christopher Schnyer, Kevin C. Chung, Soeren MattkeAbstract:e18535 Background: There are concerns about a possible association between anaplastic Large Cell Lymphoma (ALCL) and breast implants. We conducted an evidence review and a structured expert consultation process on ALCL and breast implants. Methods: We recruited a multidisciplinary panel to participate in a structured expert consultation process to evaluate the evidence for the association, its clinical significance, and a potential biological model based on their interpretation of the published evidence. The process involved a systematic literature review, development of 65 statements related to ALCL and breast implants, and two rounds of panelists’ ratings of the statements integrated with a face-to-face discussion. Data from the final ratings were synthesized and analyzed. Results: Panelists agreed that (1) there is a positive association between breast implants and ALCL development but likely under-recognition of the true number of cases; (2) a recurrent, clinically evident seroma occurring ≥ 6 months ...
Roberto N Miranda - One of the best experts on this subject based on the ideXlab platform.
-
best practices guideline for the pathologic diagnosis of breast implant associated anaplastic Large Cell Lymphoma
Journal of Clinical Oncology, 2020Co-Authors: Elaine S Jaffe, Mark W. Clemens, Roberto N Miranda, Philippe Gaulard, Binita S Ashar, Andrew L Feldman, Aliyah R Sohani, Timothy Stenzel, Sung W YoonAbstract:PURPOSETo provide guidelines for the accurate pathologic diagnosis of breast implant–associated anaplastic Large Cell Lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected ...
-
Breast implant-associated anaplastic Large Cell Lymphoma: a review
Modern Pathology, 2019Co-Authors: Andrés E. Quesada, Mark W. Clemens, L. Jeffrey Medeiros, Maria C. Ferrufino-schmidt, Sergio Pina-oviedo, Roberto N MirandaAbstract:Breast implant-associated anaplastic Large Cell Lymphoma is a newly recognized provisional entity in the 2017 revision of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. It is an uncommon, slow growing T-Cell Lymphoma with morphology and immunophenotype similar to anaplastic Lymphoma kinase-negative anaplastic Large Cell Lymphoma. However, the presentation and treatment are unique. Breast implant-associated anaplastic Large Cell Lymphoma often presents as a unilateral effusion confined to the capsule of a textured-surface breast implant, a median time of 9 years after the initial implants have been placed. Although it follows an indolent clinical course, breast implant-associated anaplastic Large Cell Lymphoma has the potential to form a mass, to invade locally through the capsule into breast parenchyma or soft tissue and/or to spread to regional lymph nodes. In most cases, an explantation with a complete capsulectomy removing all disease, without chemotherapy is considered to be curative and confers an exCellent event free and overall survival. Here we provide a comprehensive review of breast implant-associated anaplastic Large Cell Lymphoma, including history, epidemiology, clinical features, imaging and pathology findings, pathologic handling, pathogenic mechanisms, model for progression, therapy and outcomes as well as an analysis of causality between breast implants and anaplastic Large Cell Lymphoma.
-
genetics of breast implant associated anaplastic Large Cell Lymphoma bia alcl
Aesthetic Surgery Journal, 2019Co-Authors: Roberto N Miranda, Naoki Oishi, Andrew L FeldmanAbstract:Breast implant-associated anaplastic Large Cell Lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-Cell non-Hodgkin Lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent studies using next-generation sequencing have revealed that BIA-ALCL has a unique pattern of genetic alterations. BIA-ALCL is consistently negative for ALCL-related gene rearrangements involving ALK, DUSP22, and TP63. However, the JAK-STAT3 pathway is constitutively activated in BIA-ALCL, which in some cases is associated with recurrent somatic mutations of JAK1 and/or STAT3. These activating mutations, which may be concurrent, are identified in 13% (3/23) and 26% (6/23) of BIA-ALCLs, respectively. Other genetic alterations include point mutations of DNMT3A and TP53. Although the number of examined cases has been limited, these findings suggest that BIA-ALCL shows more uniform molecular features than systemic and primary cutaneous ALCLs, which show considerable genetic heterogeneity. Targeted therapies inhibiting JAK-STAT signaling are being developed and may offer novel therapeutic options for patients with BIA-ALCL, especially those with advanced disease.
-
how to diagnose and treat breast implant associated anaplastic Large Cell Lymphoma
Plastic and Reconstructive Surgery, 2018Co-Authors: Mark W. Clemens, Garry S. Brody, Raman C Mahabir, Roberto N MirandaAbstract:Learning Objectives:After reading this article, the participant should be able to: 1. Describe the diagnostic criteria for breast implant–associated (BIA) anaplastic Large Cell Lymphoma (ALCL). 2. Appropriately evaluate a patient with suspected BIA-ALCL, including appropriate imaging, laboratory tes
-
u s epidemiology of breast implant associated anaplastic Large Cell Lymphoma
Plastic and Reconstructive Surgery, 2017Co-Authors: Erin L Doren, Roberto N Miranda, Jeffrey L Medeiros, Charles E Butler, Jesse C Selber, Patrick B Garvey, Jun Liu, Mark W. ClemensAbstract:Background:Breast implant–associated anaplastic Large Cell Lymphoma (ALCL) is a distinctive type of T-Cell Lymphoma that arises around breast implants. Although rare, all cases with adequate history have involved a textured breast implant. The objective of this study was to determine the U.S. incide
Georges Delsol - One of the best experts on this subject based on the ideXlab platform.
-
cutaneous presentation of alk positive anaplastic Large Cell Lymphoma following insect bites evidence for an association in five cases
Haematologica, 2010Co-Authors: Laurence Lamant, Elaine S Jaffe, Laurence Brugieres, Stefano Pileri, Elena Sabattini, Georges DelsolAbstract:Background Skin involvement is frequent in ALK-positive anaplastic Large Cell Lymphomas. The role of an insect bite as a triggering event has been postulated but not well documented. Design and Methods We retrospectively investigated five cases of ALK-positive anaplastic Large Cell Lymphoma who presented with skin lesions occurring after an insect bite. Biopsies were immunostained with antibodies against CD30, ALK, T- and B-Cell antigens. Results Persistent skin lesions developed after solitary insect bites in three patients and after multiple bites in two. Regional lymphadenopathy developed within weeks after the bite in three cases. In four cases the correct diagnosis was delayed due to misinterpretation of the findings as a reactive infiltrate in the skin (n=2) or lymph nodes (n=2); all cases subsequently showed small numbers of Cells with nuclear and cytoplasmic staining for ALK. The final diagnoses were lymphohistiocytic variant (n=3) and composite common/small Cell type (n=2) anaplastic Large Cell Lymphoma. The patients were treated and three were alive at the last follow-up. Two patients died, one of pneumonia and the other of disseminated disease. Conclusions In these cases the sequence of events between the insect bites and the occurrence of both skin lesions and satellite lymphadenopathy suggest a direct relationship between the bite and the presentation with anaplastic Large Cell Lymphoma. We postulate that insect bite-associated antigens could result in an influx of T lymphocytes, some bearing the t(2;5). The subsequent release of cytokines at the site of the bite could act as a ‘second hit’, eliciting activation of the latter Cells, which would then express the oncogenic NPM-ALK protein and undergo uncontrolled proliferation.
-
alk positive anaplastic Large Cell Lymphoma mimicking nodular sclerosis hodgkin s Lymphoma report of 10 cases
The American Journal of Surgical Pathology, 2006Co-Authors: Jose Vassallo, Pierre Brousset, Laurence Lamant, Laurence Brugieres, Fanny Gaillard, Elias Campo, Georges DelsolAbstract:Abstract:Anaplastic Large Cell Lymphoma (ALCL) and Hodgkin Lymphoma (HL) are recognized as biologically distinct entities. However, occasionally, these two entities may share some morphologic features responsible for diagnostic difficulties. In the last 10 years, we have collected 380 cases of ALK-p
Courtney A Gidengil - One of the best experts on this subject based on the ideXlab platform.
-
breast implant associated anaplastic Large Cell Lymphoma a systematic review
Plastic and Reconstructive Surgery, 2015Co-Authors: Courtney A Gidengil, Zachary Predmore, Soeren Mattke, Kristin R Van Busum, Benjamin KimAbstract:Background:There is substantial evidence that a type of anaplastic Large Cell Lymphoma (ALCL) is associated with breast implants. However, the course in patients with breast implants seems to be unusually benign compared with other systemic ALCL. The purpose of this study was to identify and analyze
-
breast implant associated anaplastic Large Cell Lymphoma updated results from a structured expert consultation process
Plastic and reconstructive surgery. Global open, 2015Co-Authors: Zachary Predmore, K Van Busum, Soeren Mattke, Courtney A GidengilAbstract:Breast implant–associated anaplastic Large Cell Lymphoma (BIA-ALCL) is an uncommon entity. We previously published a systematic literature review of 29 cases of BIA-ALCL1 (recapitulated in a 2011 Food and Drug Administration alert)2 and a subsequent report from a structured, expert consultation panel, which agreed that there is a positive association between breast implants and anaplastic Large Cell Lymphoma (ALCL) development; anaplastic Lymphoma kinase (ALK)-negative ALCL that develops around breast implants is a clinically indolent disease with a favorable prognosis that is distinct from systemic ALK-negative ALCL; management should consist of removal of the involved implant and capsule, which is likely to prevent recurrence, and evaluation for other sites of disease; and adjuvant radiation or chemotherapy should not be offered to women with capsule-confined disease.3 Since then, additional BIA-ALCL case reports and series have been published,4–30 which we have summarized in an updated systematic review.31 Although BIA-ALCL has become increasingly recognized in the plastic surgery community, there has been little additional guidance made available to hematology/oncology providers as to how the diagnosis, management, and surveillance of this disease should be undertaken. Because much of the information in the literature is still incomplete and does not address important clinical topics related to BIA-ALCL, we conducted a follow-up structured expert consultation process that combined published evidence with expert assessment to garner additional insight on these important issues.
Andrew L Feldman - One of the best experts on this subject based on the ideXlab platform.
-
best practices guideline for the pathologic diagnosis of breast implant associated anaplastic Large Cell Lymphoma
Journal of Clinical Oncology, 2020Co-Authors: Elaine S Jaffe, Mark W. Clemens, Roberto N Miranda, Philippe Gaulard, Binita S Ashar, Andrew L Feldman, Aliyah R Sohani, Timothy Stenzel, Sung W YoonAbstract:PURPOSETo provide guidelines for the accurate pathologic diagnosis of breast implant–associated anaplastic Large Cell Lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected ...
-
genetics of breast implant associated anaplastic Large Cell Lymphoma bia alcl
Aesthetic Surgery Journal, 2019Co-Authors: Roberto N Miranda, Naoki Oishi, Andrew L FeldmanAbstract:Breast implant-associated anaplastic Large Cell Lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-Cell non-Hodgkin Lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent studies using next-generation sequencing have revealed that BIA-ALCL has a unique pattern of genetic alterations. BIA-ALCL is consistently negative for ALCL-related gene rearrangements involving ALK, DUSP22, and TP63. However, the JAK-STAT3 pathway is constitutively activated in BIA-ALCL, which in some cases is associated with recurrent somatic mutations of JAK1 and/or STAT3. These activating mutations, which may be concurrent, are identified in 13% (3/23) and 26% (6/23) of BIA-ALCLs, respectively. Other genetic alterations include point mutations of DNMT3A and TP53. Although the number of examined cases has been limited, these findings suggest that BIA-ALCL shows more uniform molecular features than systemic and primary cutaneous ALCLs, which show considerable genetic heterogeneity. Targeted therapies inhibiting JAK-STAT signaling are being developed and may offer novel therapeutic options for patients with BIA-ALCL, especially those with advanced disease.
-
genetics of anaplastic Large Cell Lymphoma
Leukemia & Lymphoma, 2016Co-Authors: Yu Zeng, Andrew L FeldmanAbstract:Anaplastic Large Cell Lymphoma (ALCL) comprises a group of T-Cell non-Hodgkin Lymphomas unified by common morphologic and immunophenotypic characteristics, but with a spectrum of clinical presentations and behaviors. Early identification of anaplastic Lymphoma kinase (ALK) gene rearrangements in some ALCLs led to recognition of ALK as an important diagnostic and prognostic biomarker, and a key driver of ALCL pathobiology. Rearrangements and other genetic abnormalities of ALK subsequently were identified in diverse other human malignancies. Recent clinical, pathologic, and genetic data have begun to shed light on ALK-negative ALCLs, revealing significant heterogeneity within this more ill-defined entity.
-
seroma associated primary anaplastic Large Cell Lymphoma adjacent to breast implants an indolent t Cell lymphoproliferative disorder
Modern Pathology, 2008Co-Authors: Anja C Roden, Andrew L Feldman, William R Macon, Gary L Keeney, Jeffrey L Myers, Ahmet DoganAbstract:Non-Hodgkin Lymphomas of the breast are rare, encompassing approximately 0.04-0.5% of all malignant breast tumors, and the vast majority are B-Cell Lymphomas. In contrast, Lymphomas of T-Cell phenotype have been rarely reported and some of these have been in close proximity to a breast implant. In our consultation practice, we have identified four patients with primary T-Cell anaplastic Large-Cell Lymphoma presenting adjacent to silicone or saline breast implants. All patients presented with seroma and neoplastic Cells were identified in suspension in the serous fluid without solid tissue invasion. Three patients had no evidence of systemic disease (stage 1E), and one patient was not staged. The mean age of the patients was 46 years (range, 34-59 years). In all patients, the neoplastic Cells had a T-Cell phenotype, expressed CD30, cytotoxic granule-associated proteins, EMA and clusterin, and were anaplastic Lymphoma kinase-1-negative. Clonal T-Cell receptor gamma-chain gene rearrangements were identified in three patients. All patients underwent capsulectomy with removal of the implant. One patient subsequently received chemotherapy and radiation therapy, and another was treated with radiation alone. The third patient received no further therapy and the fourth patient has been recently diagnosed. After a mean time of 13 months (range, 9-20 months), all three patients with follow-up were alive and well without any recurrence or systemic disease. Although the follow-up time was relatively short, our series and other reported cases suggest that primary anaplastic Large-Cell Lymphoma adjacent to breast implants is an indolent T-Cell lymphoproliferative disorder.
